Trial Profile

Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms ALTERNATE

Most Recent Events

10 Jan 2025 Planned primary completion date changed from 31 Aug 2025 to 27 Feb 2014.
13 Apr 2022 Results assessing effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination presented at the 113th Annual Meeting of the American Association for Cancer Research
11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com